

Index

- aAA. *See* acquired aplastic anemia
 abdomen, physical examination of, 32
 ABO incompatibility, 36
 HSCt and, 181
 acanthocytes, 27
 ACD. *See* anemia of chronic inflammation
 ACI. *See* anemia of chronic inflammation
 acquired aplastic anemia (aAA), 128–32. *See also* paroxysmal nocturnal hemoglobinuria
 bone marrow with, 128
 clinical presentation of, 129
 clonal hematopoiesis and, 129
 diagnostic evaluation of, 129–30
 epidemiology of, 128
 etiology of, 128
 laboratory findings for, 129–30
 pathophysiology, 128–9
 prognosis, 129
 severity grading of, 131
 treatment, 129–32
 through BMT, 130–1
 eltrombopag therapy, 132
 IST, 131
 second-line therapies, 131–2
 acquired sideroblastic anemias, 44
 causes of, 45
 pathophysiology, 44–5
 prognosis of, 46
 treatment of, 46
 acquired stomatocytosis, 106
 acute chest syndrome (ACS), 68, 73
 acute hemolytic transfusion reactions, 208–9
 acute large volume blood loss, 202
 acute lung injury (ALI), 211
 acute PCH, 93
 Acute Vaso-Occlusive Crisis (VOC), 66
 aging, anemia of
 clinical significance of, 187
 dementia, 187
 epidemiology of, 185–6
 inflammation and, 186–7
 hepcidin levels, 186
 leptin protein, 186
 MIF, 186
 TNF- α , 186
 vitamin D deficiency, 186–7
 management strategies, 187–8
 prevalence of, 185
 aHUS. *See* atypical hemolytic uremic syndrome
 AIHA. *See* autoimmune hemolytic anemia
 alcohol use, non-megaloblastic macrocytic anemias from, 63
 alemtuzumab, 134
 ALI. *See* acute lung injury
 Alpha-thalassemia, 53–6
 causes of, 53
 Hb Barts hydrops fetalis syndrome, 55–6
 diagnosis of, 55
 epidemiology of, 55
 prevention of, 55–6
 HbH disease, 53–5
 clinical vignette for, 54–5
 diagnosis of, 54
 hematologic data on, 54
 nondeletional, 53
 syndromes, 54–5
 treatment of, 54
 traits of, 53
 amegakaryocytic thrombocytopenia, 148
 anemia in cancer patients, 172
 ACI and, 172
 chemotherapy-associated anemia, 220–1
 diagnosis of, 173–5
 differential, 174
 iron deficiency in, 174
 epidemiology, 172
 erythropoietin therapy for, 175
 etiology of, 172–3
 evaluation of, 173–5
 management of, 175–7
 through RBC transfusion, 175
 with rhEPO, 172, 174–7
 pathogenesis of, 172–3
 pathophysiology, 198
 therapy-related toxicity
 grading, 172
 transfusion, 175
 anemia of chronic inflammation (ACI)
 cancer and, 172
 case study for, 153–4
 clinical presentation, 152–3, 194
 critical illness with, 151
 cytokines, 196
 diagnostic evaluation, 153, 194–5
 epidemiology, 150–1
 autoimmune diseases, 150
 from infections, 150
 erythropoiesis, 196, 198
 etiology, 150–1
 in general population, 150
 hepcidin expression, 195–6
 incidence rates for, 151
 iron, 196
 lab findings, 153, 194–5
 pathophysiology, 151–2, 195–6
 erythrocyte turnover, 152
 erythropoiesis, 196, 198
 hepcidin regulation, 152, 195–6
 hypoferremia, 152
 hypoproliferative effects, 151–2
 inflammatory cytokines, 151–2
 iron metabolism, 196
 iron-restricted erythropoiesis, 152
 pro-inflammatory cytokines, 196
 RA and, 150
 soluble transferrin receptor and, 153
 treatment and prognosis, 153, 198–9
 with ESA, 198–9
 anemia of inflammation, 169
 anemia of prematurity, 34
 anemias. *See also* clinical approaches; *specific anemias*
 causes of, xi, 1
 through blood loss, 24
 classification of, 24
 through MCV, 24
 clinical definitions of, xi, 23
 comorbidities with, xi
 defined, 172, 185
 diagnostic approach, 23–4
 through bone marrow aspirate specimens, 24
 through peripheral blood smears, 24–5, 29
 future approaches to, 230–3
 hemoglobin deficiency in, xi
 hyperproliferative, 29. *See also specific anemias*
 hypoproliferative, 24–9. *See also specific anemias*
 leukemias and, xi
 mild, 1
 multiple myelomas and, xi
 overview of, 229–30
 prevalence rates, 23
 risk factors for, xi
 individual, 2
 severe, 1
 symptoms of, 1
 antibiotics, after splenectomy, 225
 anticonvulsants, 31
 antithymocyte globulin (ATG), 131
 aplasia, 133–4
 aplastic anemia, 128–32
 asplenia. *See* functional asplenia
 ATG. *See* antithymocyte globulin
 atypical hemolytic uremic syndrome (aHUS), 113–14
 clinical presentation of, 117
 complement defects, 114
 diagnostic evaluation, 118
 laboratory findings, 118
 pathophysiology, 116

Index

- renal transplantation for, 120
 treatment for, 120
 auto-antibodies, in PCH, 92
 autoimmune hemolytic anemia (AIHA). *See also* cold agglutinin disease; paroxysmal cold hemoglobinuria; warm AIHA
 classification of, 84–5
 epidemiology, 84
 HSCT and, 182
 during pregnancy, 191
 prevalence of, 85
 splenectomy for, 223
 autoimmune TTP, 113
 avascular necrosis (AVN), 70, 73
 azathioprine, 93
 AZT. *See* zidovudine
- babesiosis, 25, 123, 205, 212
 bacterial infectious disease, 194
 Barts hydrops fetalis syndrome, Hemoglobin, 55–6
 diagnosis, 55
 epidemiology, 55
 prevention of, 55–6
 basophilic stippling, 24–5
 Beta-thalassemia, 49–53
 deletions as cause of, 49
 dominant, 49
 HbE form, 53
 intermedia form, 52–3
 mutations of, 49
 silent, 49
 pathophysiology, 49
 traits of, 49–50
 clinical vignettes, 49–50
 Beta-thalassemia major, 50–2
 clinical vignette for, 52
 complication of, 50–2
 endocrinopathy and, 51
 extramedullary hematopoiesis and, 51
 growth delay and, 51
 from iron overload, 51
 management of, 50–2
 osteoporosis and, 51
 preventive programs, 52
 treatment of, 51
 through bone-marrow transplantation, 51–2
 through disease-modifying therapies, 51–2
 transfusions in, 50–1
 BFU-E. *See* burst forming units-erythroid
 bilirubin levels, 12
 biosynthesis, hemoglobin and, 6–8
 bite cells, 24–5
 blister cells, 24–5
 blood loss, 24
 acute large volume, 202
 chronic, 41
 blood transfusions. *See also* red cell transfusion therapy; transfusion reactions
 for anemia in cancer patients, 175
 for CAD, 91
 ESA therapy as alternative to, 221
 for malaria treatment, 111
 of RBCs, xi
 for Beta-thalassemia major, 50–1
 engineered stem cells in, xi
 twin-twin, 35
 WAIHA and, 87
 BMSC. *See* bone marrow stromal cells
 BMT. *See* bone marrow transplantation
 bone marrow
 EPO in, 23
 HIV associated with anemia, 168
 marrow suppression and, 167–8
 sideroblastic anemias and, 45–6
 transplantation of, for Beta-thalassemia major, 51–2
 bone marrow aspirate specimens, 24
 bone marrow failure
 acquired, 128–32
 congenital, 143–8
 bone marrow stromal cells (BMSC), 198
 bone marrow transplantation (BMT)
 for aAA, 130–1
 HSCT and, anemia after, 182
 for PNH, 141
 brain issues, with SCD, 69
 burr cells, 24–5
 burst forming units-erythroid (BFU-E), 6, 14, 198
- Cabot rings, 24–5
 CAD. *See* cold agglutinin disease
 CAMT. *See* congenital amegakaryocytic thrombocytopenia
 cancer. *See* anemia in cancer patients
 cardiac valves. *See* prosthetic cardiac valves
 cardiovascular systems
 physical examination of, 32
 with SCD, 70
 cART. *See* combined anti-retroviral therapy
 case studies
 ACI, 153–4
 DIHA, 97–8
 megaloblastic macrocytic anemias, 64–5
 non-megaloblastic macrocytic anemias, 65
 red cell transfusion therapy, 205
 for sideroblastic anemias, 47
 CD47 proteins, 20–1
 central nervous system, with SCD, 69–70
 brain issues, 69
 eye issues, 69–70
 neurocognitive impairments, 69
 CFU-E. *See* colony forming units-erythroid
 chaperone proteins, 8
 chemotherapy-associated anemia, 220–1
 CHF. *See* chronic heart failure
 childhood anemias. *See also* hemolytic anemia in children
 anemia of prematurity, 34
 DIHA, 96
 general considerations for, 34–5
 hemoglobin abnormalities as factor in, 34
 in infants. *See also specific anemias*
 causes of, 35
 physiologic anemia of infancy, 34
 neonatal hemolytic anemia due to maternal alloimmunization, 35–6
 ABO incompatibility as cause of, 36
 HDN as factor in, 35–6
 neonatal hemorrhagic anemia, 35
 fetal maternal hemorrhage and, 35
 from twin-twin transfusions, 35
 from nutritional deficiencies, 36
 iron deficiency, 36, 41
 vitamin B12 deficiency, 36
 physiologic anemia of childhood, 35
 RBC characteristics for, 35
 from RBC hypoplastic disorders, 38
 DBA, 38
 TEC of childhood, 38
 red cell transfusion therapy for, 205
 chimerism, 180
 chromosomal fragility, 129–30.
See also Diamond-Blackfan anemia
 chronic blood loss. *See* blood loss
 chronic heart failure (CHF), 198
 chronic kidney disease (CKD), 220
 chronic leg ulcers. *See* leg ulcers
 chronic liver disease, 196–8
 chronic obstructive pulmonary disease (COPD), 63
 chronic PCH, 93
 chronic renal disease, 196
 CKD. *See* chronic kidney disease
 classical PNH, 138
 treatment for, 139
 clindamycin, 124
 clinical approaches, to anemias, 30–3
 through medical history, 30–2
 current medications, 31
 family history factors, 31–2
 gynecological history factors, 31
 for past illnesses, 31
 for present illnesses, 30
 social history factors, 31
 surgical history factors, 31
 systems review in, 30–1
 through physical examination, 32–3
 of abdomen, 32
 of cardiovascular systems, 32
 of extremities, 33
 of genitourinary system, 33
 of HEENT, 30–2
 of neck, 32
 of neurological systems, 33
 of pulmonary system, 32
 of skin, 32
 of vital signs, 32
 clopidogrel, 116
 clostridial sepsis, hemolytic anemia from, 123–4
 clinical features, 123–4
 pathophysiology, 123–4
 treatment of, 124
 codocytes, 24–5
 cognitive deficiencies, 1
 cold agglutinin disease (CAD), 89–92
 associated conditions, 90
 clinical features, 92
 Coombs test, 89
 laboratory features, 89
 management of, 91–2
 with cold avoidance, 90
 with pharmacologic therapy, 91–2
 with RBC transfusions, 91
 steroid therapy, 92
 mechanism of hemolysis, 90
 cold agglutinins, 89–90
 cold AIHA. *See* cold agglutinin disease
 cold avoidance, 90
 colony forming units-erythroid (CFU-E), 6, 14, 198
 combined anti-retroviral therapy (cART), 167, 169–70

Index

- congenital amegakaryocytic thrombocytopenia (CAMT), 148
 congenital TTP, 113, 119
 congestive heart failure (CHF), 1, 32
 conjunctiva, 69–70
 conjunctival pallor, 32
 connective tissue diseases, 194
 Coombs test
 for CAD, 89
 for PCH, 92
 for WAIHA, 84–6
 clinical serological associations, 86
 COPD. *See* chronic obstructive pulmonary disease
 copper, ingestion of, 124
 corticosteroid therapy
 for DBA, 144
 for PRCA, 133–4
 for WAIHA, 89
 cretated RBC, 24–5
 cyclophosphamide, 93, 134
 cytokines
 ACI, 196
 with ACI, 151–2
 immune, 109
 cytopenias. *See* acquired aplastic anemia
- dacryocytes, 24–5
 dactylitis, 70, 73
 danazol, 132
 dapsone, 168
 darbepoetin alfa, 219, 221
 DAT. *See* direct antiglobulin test
 DBA. *See* Diamond-Blackfan anemia
 DC. *See* dyskeratosis congenita
 deferasirox, 73
 deferiprone, 163
 deferoxamine, 73, 163
 degmacytes, 24–5
 delayed hemolytic transfusion reaction (DHTR), 209–10
 delayed serologic transfusion reaction (DSTR), 210
 destruction, of RBCs, 11–12, 21
 bilirubin levels, 12
 extravascular, 12
 geometric hypothesis, 12
 immunological hypothesis, 12
 metabolic hypothesis, 11–12
 rates of, 12
 through reticuloendothelial system clearance, 21
 DHTR. *See* delayed hemolytic transfusion reaction
 Diamond-Blackfan anemia (DBA), 38, 144
 corticosteroid therapy for, 144
 impaired ribosome function, 144
 DIHA. *See* drug-induced immune hemolytic anemia
- direct antiglobulin test (DAT), 97
 drepanocytes, 24–5
 drug-induced immune hemolytic anemia (DIHA), 87
 case study for, 97–8
 clinical presentation of, 96
 in adults, 96
 in pediatric populations, 96
 diagnostic evaluation of, 97
 drugs as cause of, 95
 epidemiology of, 95
 etiology of, 95
 laboratory findings, 97
 with DAT, 97
 elution and, 97
 with IAT, 97
 pathophysiology, 95–6
 with drug-dependent antibody mechanism, 95–6
 with drug-independent antibody mechanism, 96
 with non-immune protein adsorption, 96
 prognosis with, 97
 treatment for, 97
 DSTR. *See* delayed serologic transfusion reaction
 dyserythropoiesis, 45, 108–9
 dyskeratosis congenita (DC), 144–6
 clinical diagnosis of, 144–6
 stem cell transplantation for, 146
 telomerase complex and, 144–6
- echinocytes, 24–5
 eculizumab, 93, 120, 139–41
 Ehrlich, Paul, 128
 elderly. *See* aging
 elliptocytes, 24–5
 eltrombopag therapy, 132
 elution, for DIHA, 97
 Embden-Meyerhof pathway, 10
 endocrinopathy, Beta-thalassemia major and, 51
 engineered stem cells, in red cell transfusions, xi
 enucleation, in reticulocyte maturation, 16–17
 EPO. *See* erythropoietin
 epoetin alfa, 219, 221
 Epstein-Barr virus, 183
 erythroblastic islands, 16
 erythrocyte membrane, 100
 erythrocytes. *See also* red blood cells
 in ACI, 152
 development of, 3
 hemoglobin content and, xi, 3
 osmolarity of, 3
 proerythroblast stage, 6
 purpose and functions of, xi
 resilience of, 3
- erythrocytic destruction and sequestration, 108
 erythropoiesis, 3
 ACI, 196, 198
 BFU-E, 6, 14
 in bone marrow, 19
 CFU-E, 6, 14
 clinical definition of, 23
 early, 14–16
 hemoglobin production and, 6
 HSCs in, 14
 iron-restricted, 152
 with malaria, immune response to, 109–10
 MEP differentiation in, 14
 primary sites of, 6
 erythropoiesis-stimulation agents (ESAs), 198–9
 blood transfusions and, as alternative to, 221
 for chemotherapy-associated anemia, 220–1
 for CKD, 220
 darbepoetin alfa, 219, 221
 dosing guidelines, 221
 epoetin alfa, 219, 221
 indications for, 220–1
 safety of, 219–20
 erythropoietin (EPO), 14–16
 production of, 23
 ESAs. *See* erythropoiesis-stimulation agents
 exercise intolerance, 1
 extramedullary hematopoiesis, 51
 extravascular hemolytic transfusion reactions, 209
 extremities, physical examination of, 33
 extrinsic non-immune hemolytic anemias
 from clostridial sepsis, 123–4
 clinical features, 123–4
 pathophysiology, 123–4
 treatment of, 124
 from heavy metal exposure, 124
 through copper ingestion, 124
 through lead poisoning, 124
 from hypersplenism, 125
 from infectious parasites, 123
 babesiosis, 123
 from IVIG, 125
 march hemoglobinuria, 123
 from prosthetic cardiac valves, 122–3
 clinical features, 122
 epidemiology of, 122
 history of, 122
 pathophysiology, 122
 treatment of, 122–3
 thermal injury-induced hemolysis, 123
 eye issues, with SCD, 69–70
- Fanconi anemia (FA), 146–7
 diagnosis of, 146–7
 genomic instability and, 146–7
 treatment for, 147
 favism, 37
 febrile non-hemolytic transfusion reactions, 210–11
 Felty Syndrome, 224
 ferric carboxymaltose, 218
 ferric gluconate, 42, 218
 ferrous fumarate, 217
 ferrous gluconate, 217
 ferrous sulfate, 217
 ferumoxytol, 42, 217–18
 fetal maternal hemorrhage, 35
 fever, after splenectomy, 225
 flippases, 9–10
 floppases, 9–10
 fludarabine, 92
 folate deficiency
 megaloblastic macrocytic anemias and, 59–63
 during pregnancy, 192
 folic acid, as hematinic, xi
 functional asplenia, 70, 73
 fungal infectious disease, 194
- G6PD deficiency. *See* glucose-6-phosphate dehydrogenase deficiency
 gallstones. *See* pigmented gallstones
 gastrointestinal system, with SCD, 70, 73
 gene therapies, advances in, xi
 genetics, hemoglobin production and, 6
 genitourinary system
 physical examination of, 33
 with SCD, 70
 geometric hypothesis, for RBC destruction, 12
 globin genes, 6–8
 chaperone proteins, 8
 duplication of, 7
 expression of, 7–8
 hemoglobin switching, 7
 LCRs in, 8
 glossitis, 30–1
 glucose-6-phosphate dehydrogenase (G6PD) deficiency, 37
 glycosylphosphatidylinositol (GPI) anchors, 137
 graft failure, HSCT and, 179–80
 blood chimerism, 180
 causes of, 179–80
 graft-versus-host-disease (GVHD), 180–2
 transfusion-associated, 213
 growth delay, Beta-thalassemia major and, 51
 GVHD. *See* graft-versus-host-disease

Index

- haptenic reactions, 87
 HbE/Beta-thalassemia, 53
 HbH disease, 53–5
 clinical vignette for, 54–5
 diagnosis of, 54
 hematologic data on, 54
 nondeletional, 53
 syndromes, 54–5
 treatment of, 54
 HDN. *See* hemolytic disease of the newborn
 HE. *See* hereditary elliptocytosis
 head, ear, eyes, nose, and throat (HEENT) examination, 30–2
 heart failure, chronic, 194
 heavy metal exposure, hemolytic anemia from, 124
 through copper ingestion, 124
 through lead poisoning, 124
 HEENT examination. *See* head, ear, eyes, nose, and throat examination
 Heinz bodies, 24–5
 HELLP. *See* hemolysis with elevated liver enzymes and low platelets
 hematinics, xi
 hematocrit, 1
 hematologic, malignancies, 194
 hematopoietic stem cell transplantation (HSCT), anemia after
 ABO incompatibility, 181
 AIHA and, 182
 BMT criteria, 182
 defined, 179
 erythropoietin insufficiency and, 179–80
 graft failure and, 179–80
 blood chimerism, 180
 causes of, 179–80
 GVHD and, 180–2
 HLH and, 183
 HUS and, 181
 pathophysiology, 179
 relapse of underlying disease, 182–3
 secondary MDS and, 182–3
 TMA and, 181–2
 TTP and, 181
 hematopoietic stem cells (HSCs), 14
 hematuria, with SCD, 70, 73
 heme, 1
 in terminal erythroid differentiation, 16
 hemichromes, 20
 hemoglobin. *See also* high affinity hemoglobin disorders; low affinity hemoglobin disorders
 anemias and, xi
 Beth Israel, 79
 in biosynthesis, 6–8
 C, 79
 C crystals, 24–5
 in childhood anemias, abnormalities of, 34
 components of, 1
 Cretail, 79
 defined, xi
 D-Los Angeles, 79
 D-Punjab, 79
 electrophoresis, 71
 erythrocytes and, xi, 3
 erythropoiesis and, 6
 F, 34
 functions of, 3–6
 oxygen binding, 5–6
 genetics and, 6
 globin genes, 6–8
 chaperone proteins, 8
 duplication of, 7
 expression of, 7–8
 hemoglobin switching, 7
 LCRs in, 8
 Hammersmith, 79
 hemolytic anemia in children and, from disorders of, 37–8
 J-Capetown, 79
 Kansas, 79, 81
 Kempsey, 79
 laboratory assessments, 2
 hematocrit, 1
 Hgb, 1
 MCH, 2
 MCHC, 2
 life cycle of, 1
 M-Boston, 79
 M-Hyde Park, 79
 M-Iwate, 79
 M-Milwaukee-I, 79
 modifications of
 non-enzymatic, 8
 post-translational, 8
 M-Osaka, 79
 M-Saskatoon, 79
 mutations, 76
 ontogeny of, 6
 oxygen and
 acquisition mechanisms, 6
 binding of, 5–6
 delivery mechanisms, 6
 salt bridges, 5
 transport, 5–6
 Philadelphia, 79
 polymerization of, 5
 precipitated, 5
 S, 79
 Santa Ana, 79
 Setif, 79
 solubility of, 5
 St. Louis, 79
 structure of, 3–6. *See also* structural hemoglobinopathies
 tetramers, 3–5
 Suresnes, 79
 Titusville, 79
 Torino, 79
 unstable, 76
 Zurich, 79
 Hemoglobin Barts hydrops fetalis syndrome, 55–6
 diagnosis, 55
 epidemiology, 55
 prevention of, 55–6
 hemoglobin switching, 7
 hemoglobin value (Hgb), 1
 hemoglobinopathies. *See also* structural hemoglobinopathies
 classifications of, 77
 unstable hemoglobin disorders, 76
 clinical manifestations of, 77
 diagnosis of, 77–80
 mutational factors for, 78–9
 pathophysiology, 76–80
 treatment for, 80
 hemoglobinuria, 137–41
 hemolysis mechanisms
 CAD, 90
 for PCH, 93
 for WAIHA, 87
 haptenic reactions, 87
 NIPA, 87
 hemolysis with elevated liver enzymes and low platelets (HELLP), 191
 hemolytic anemia in children, 36–8
 causes of, 36
 chronic disorders and, 36–7
 clinical indicators of, 36
 from hemoglobin disorders, 37–8
 from RBC enzyme disorders, 37
 favism, 37
 G6PD deficiency, 37
 PK deficiency, 37
 from RBC membrane disorders, 37
 HS, 37
 sickle cell anemia and, 37–8
 hemolytic anemias, 29–30. *See also* specific hemolytic anemias
 AIHA. *See also* cold agglutinin disease; paroxysmal cold hemoglobinuria; warm AIHA
 classification of, 84–5
 epidemiology, 84
 HSCT and, 182
 prevalence of, 85
 common acquired causes of, 29–30
 drug-induced immune, 87
 during pregnancy, 191–2
 hemolytic disease of the newborn (HDN), 35–6
 hemolytic transfusion reactions, 208–9
 acute, 208–9
 DHTR, 209–10
 DSTR, 210
 extravascular, 209
 intravascular, 209
 nonimmune-mediated, 210
 with SCD, 210
 severity of, 208
 hemolytic uremic syndrome (HUS), 181
 during pregnancy, 191
 hemophagocytic lymphohistiocytosis (HLH), 183
 hemozoin, 109
 hepcidin expression, 39–40, 195–6
 ACI, 195–6
 with ACI, 152
 aging with anemia, 186
 hereditary elliptocytosis (HE), 104–5
 classification of, 104
 clinical presentation of, 104
 diagnostic evaluation of, 105
 incidence rates for, 104
 inheritance rates for, 104
 laboratory findings for, 105
 pathophysiology, 104
 spectrin abnormalities, 104
 treatment for, 105
 hereditary pyropoikilocytosis (HPP), 104–5
 clinical presentation of, 104
 diagnostic evaluation of, 105
 incidence rates for, 104
 inheritance rates for, 104
 laboratory findings for, 105
 pathophysiology, 104
 spectrin abnormalities, 104
 SAO and, 104
 treatment for, 105
 hereditary sideroblastic anemias
 causes of, 44
 pathophysiology, 44
 prognosis for, 46
 treatment of, 46
 hereditary spherocytosis (HS), 100–3
 classification of, 101
 clinical presentation of, 100–1
 jaundice and, 101
 complications from, 101–2
 diagnostic evaluation of, 102–3
 epidemiology of, 100
 etiology of, 100
 hemolytic anemia in children and, 37
 laboratory findings for, 102–3
 EMA binding, 102
 MCHC, 102

Index

- hereditary spherocytosis (HS) (cont.)
 MCV, 102
 osmotic fragility testing, 102
 with peripheral blood smears, 102
 pathophysiology, 100
 primary defects, 100
 secondary defects, 100
 prognosis with, 103
 splenomegaly and, 103
 treatment for, 103
 with splenectomy, 103, 223
- hereditary stomatocytosis
 syndromes
 acquired stomatocytosis, 106
 classification criteria for, 105
 HX, 105–6
 hydrocytosis, 105
 intermediate syndromes, 106
 Rh null disease and, 106
 sistosterolemia and, 106
 Tangier disease and, 106
- hereditary xerocytosis (HX), 105–6
- hexose monophosphate shunt (HMPS), 11
- Hgb. *See* hemoglobin value
- high affinity hemoglobin disorders, 76, 80–1
 diagnosis of, 80–1
 pathophysiology, 80
 treatment of, 81
- HIV. *See* human immunodeficiency virus
- HLH. *See* hemophagocytic lymphohistiocytosis
- HMPS. *See* hexose monophosphate shunt
- HMW iron dextran, 218
- homeostasis. *See also* volume homeostasis disorders
 for RBs, 10–11
- homozygous alpha thalassemia, 34
- Howell-Jolly bodies, 218
- HPP. *See* hereditary pyropoikilocytosis
- HS. *See* hereditary spherocytosis
- HSCs. *See* hematopoietic stem cells
- HSCT. *See* hematopoietic stem cell transplantation
- HTN. *See* pulmonary hypertension
- human immunodeficiency virus (HIV), anemia associated with, 168–9
 anemia of inflammation, 169
 clinical presentation, 169
 diagnostic evaluation, 169–70
 epidemiology, 167
 etiology, 167
 MDS and, 169
 medications as factor in, 168
- pathophysiology, 167–9
 G6PD deficiency, 168
 hemolysis, 168
 hypogonadism, 167
 infection of stem cells and progenitors, 168–9
 infiltration of bone marrow, 168
 marrow suppression, 167–8
 nutritional deficiencies, 167
 opportunistic infections in, 168
 treatment and prognosis, 170
 cART, 167, 169–70
 vitamin B12 deficiency, 167
- HUS. *See* hemolytic uremic syndrome
- HX. *See* hereditary xerocytosis
- hydrocytosis. *See* overhydrated stomatocytosis
- hydroxyurea, 72
- hyperkalemia, 214
- hypersplenism, 125. *See also* chronic liver disease
- hypochromia, 24–5
- hypoferremia, 152
- hypogonadism, 167
- hypokalemia, 214
- hypoplastic disorders, of RBCs, 38
 DBA, 38
 TEC of childhood, 38
- hypoplastic PNH, 138
- hyposthenuria, 70
- hypothermia, 214
- hypothyroidism, 194
- hypothyroidism, non-megaloblastic macrocytic anemias and, 63
- IAT. *See* indirect antiglobulin test
- IBMFs. *See* inherited bone marrow failure syndromes
- IDA. *See* iron deficiency anemia
- idiopathic sideroblastic anemias, 46
- imatinib, 174
- immune cytokines, 109
- immunological hypothesis, for RBC destruction, 12
- immunosuppressive therapy (IST), 131
 for MDS, 163
- impaired ribosome function, 144
- indirect antiglobulin test (IAT), 97
- infants
 anemias in. *See also specific anemias*
 causes of, 35
 physiologic anemia of infancy, 34
 red cell transfusion therapy in, 205
- infectious parasites, hemolytic anemia from, 123
- infiltration of bone marrow, 168
- inflammatory bowel diseases, 194
- inherited bone marrow failure syndromes (IBMFs)
 CAMT, 148
 clinical presentations of, 143
 DBA, 38, 144
 corticosteroid therapy for, 144
 impaired ribosome function, 144
 DC, 144–6
 clinical diagnosis of, 144–6
 stem cell transplantation for, 146
 FA, 146–7
 diagnosis of, 146–7
 treatment for, 147
 Pearson syndrome, 148
 SCN, 148
 SDS, 143–7
 clinical presentation, 147
 diagnosis of, 147
 management of, 148
 SBDS gene, 147–8
 TAR syndrome, 148
- International Prognostic Scoring System (IPSS), 160–1
- intraoperative transesophageal echocardiography (TEE), 122
- intravascular hemolytic transfusion reactions, 209
- intravenous immune globulin (IVIG), 125
- IPSS. *See* International Prognostic Scoring System
- iron
 absorption requirements, 39
 ACI, 196
 anemia in cancer patients and, 174
 Beta-thalassemia major and, 51
 as hematinic, xi
 hepcidin expression, 39–40
 recycling of, 40
 rhEPO supplemented with, 177
 sideroblastic anemias and, 45
 in terminal erythroid differentiation, 16
- iron deficiency
 in anemia in cancer patients, 174
 in childhood anemias, 36, 41
 during pregnancy, 190
- iron deficiency anemia (IDA)
 causes of, 41
 chronic blood loss as, 41
 in childhood, 36
- clinical presentation of, 40–1
 diagnostic evaluation of, 40–1
 through peripheral blood smear review, 40–1
 through TIBC, 40–1
 with TSAT testing, 40–1
 epidemiology of, 39
 nutritional, 36, 41
 pathophysiology, 39–40
 prevention strategies, 41–2
 treatment of, 41–2
 with parenteral iron salts, 42
 Von Willebrand's disease, 41
 in women, 41
- iron sucrose, 42, 218
- iron-restricted erythropoiesis, 152
- irradiation, 204
- IST. *See* immunosuppressive therapy
- IVIG. *See* intravenous immune globulin
- kidney disease, chronic, 194
- kolonychia, 32
- Kussmaul's sign, 32
- laparoscopic splenectomy, 224
- large granular lymphocyte, 132
- LCR. *See* Locus Control Region
- lead poisoning, 124
- leg ulcers, chronic, 70, 73
- lenalidomide, 162
- leukemias, anemias and, xi
- leukoreduction, 204
- lipid components, of RBCs, 9–10
- liver disease. *See* hypersplenism
- liver disease, chronic, 194
- LMW iron dextran, 218
- Locus Control Region (LCR), 8
- low affinity hemoglobin disorders, 76, 81
 cyanosis and, 81
 diagnosis of, 81
 pathophysiology, 81
 treatment for, 81
- macrocytes, 24–5, 59–60
- macrocytic anemias. *See also* megaloblastic macrocytic anemias; non-megaloblastic macrocytic anemias
 defined, 59
 MCV and, 59
- macrophage migration inhibitory factor (MIF), 110, 186
- MAHA. *See* microangiopathic hemolytic anemia
- malaise, 1
- malaria
 clinical presentation of, 110
 diagnosis of, 110
 epidemiology of, 108

Index

- etiology of, 108
 morbidity of, 111
 pathophysiology, 108–10
 dyserythropoiesis, 108–9
 erythrocytic destruction and sequestration, 108
 erythropoiesis, immune response and, 109–10
 hemozoin, 109
 host immunity, 109
 immune cytokines, 109
 MIF inhibition, 110
 prognosis with, 110–11
 red blood cells, 24–5
 treatment of, 110–11
 with exchange transfusion, 111
 march hemoglobinuria, 123
 mature RBCs. *See* reticulocyte maturation
 MCH. *See* mean corpuscular hemoglobin
 MCHC. *See* mean corpuscular hemoglobin concentration
 MCV. *See* mean corpuscular volume
 MDS. *See* myelodysplastic syndromes
 mean corpuscular hemoglobin (MCH), 2
 mean corpuscular hemoglobin concentration (MCHC), 2, 102
 mean corpuscular volume (MCV), 24
 for HS, 102
 macrocytic anemias and, 59
 reticulocyte count and, 24–30
 megakaryocyte/erythroid (MEP) lineages, 14
 megaloblastic macrocytic anemias, 59–63
 case study for, 64–5
 clinical presentation of, 61
 diagnostic evaluation of, 61–2
 differential, 59–60
 epidemiology of, 59
 etiology of, 59
 folate deficiency and, 59–63
 lab findings for, 61–2
 pathophysiology, 59–61
 peripheral blood smear, 61–2
 during pregnancy, 190
 prognosis with, 63
 treatment of, 63
 vitamin B12 deficiency and, 59–63
 MEP lineages. *See* megakaryocyte/erythroid lineages
 metabolic derangements, 213–14
 metabolic hypothesis, for RBC destruction, 11–12
 metabolism, of RBCs, 10–11
 metformin, 31
 methemoglobinemia, 81–3
 causes of, 82
 clinical presentation of, 81–2
 diagnosis of, 82
 pathophysiology, 82
 treatment of, 82–3
 methotrexate, 31
 methyl dopa, 95
 MF. *See* myelofibrosis
 microangiopathic hemolytic anemia (MAHA). *See also* atypical hemolytic uremic syndrome; thrombotic thrombocytopenic purpura
 classification of, 114
 diagnostic evaluation of, 117–18
 epidemiology of, 113–14
 etiology of, 113–14
 laboratory findings, 117–18
 during pregnancy, 191
 secondary thrombotic microangiopathy, 114
 pathophysiology, 116
 treatment for, 120
 STEC-HUS, 113
 clinical presentation of, 117
 diagnostic evaluation, 118
 laboratory findings, 118
 pathophysiology, 115–16
 treatment for, 119
 microcytes, 24–5
 microspherocytosis, 84
 MIF. *See* macrophage migration inhibitory factor
 mild anemias, comorbidities with, 1
 Moyamoya syndrome, 69
 multiple myelomas, anemias and, xi
 musculoskeletal system, with SCD, 70
 mutations
 of Beta-thalassemia, 49
 silent, 49
 hemoglobin, 76
 myelodysplastic syndromes (MDS)
 classification of, 160–2
 with IPSS, 160–1
 WHO subtypes, 160
 clinical presentation, 157–8
 diagnostic evaluation, 158–60
 epidemiology, 156–7
 risk factors, 157
 5q-syndrome, 144
 in higher risk patients, 163
 HIV and, 169
 iron overload, 163
 in lower risk patients, 162–3
 treatment for, 162–3
 pathophysiology, 156–7
 common genetic abnormalities, 157
 pediatric, 156
 primary, 156
 prognosis with, 160–2
 secondary, 156
 HSCT and, 182–3
 sideroblastic anemias and, 44, 46
 treatment for, 162
 with ESAs, 162–3
 with hypomethylating agents, 163
 with IST, 163
 with lenalidomide, 162
 lower risk patients, 162–3
 myelofibrosis (MF), 224
 neck, physical examination of, 32
 neonatal hemolytic anemia due to maternal alloimmunization, 35–6
 ABO incompatibility as cause of, 36
 HDN as factor in, 35–6
 neonatal hemorrhagic anemia, 35
 fetal maternal hemorrhage and, 35
 from twin-twin transfusions, 35
 neonates. *See* infants
 neurological systems
 physical examination of, 33
 with SCD, 69
 neuropathic pain, with SCD, 67
 NIPA. *See* non-immune protein adsorption
 nitric oxide levels, 139
 nondeletional HbH disease, 53
 non-enzymatic modifications, of hemoglobin, 8
 non-immune protein adsorption (NIPA), 87
 non-immune protein adsorption, in DIHA, 96
 nonimmune-mediated transfusion reactions, 210
 non-megaloblastic macrocytic anemias, 63–4
 from alcohol use, 63
 case study for, 65
 clinical presentation of, 63
 COPD and, 63
 diagnostic evaluation of, 63–4
 differential, 59–60
 epidemiology of, 63
 etiology of, 63
 hypothyroidism and, 63
 pathophysiology, 63
 prognosis with, 63–4
 treatment for, 63–4
 non-proliferative retinopathy, 69
 normovolemic anemia, 202–4
 chronic anemia and, 203–4
 irradiation, 204
 leukoreduction, 204
 RCE, 204
 washed red cells, 204
 nucleated red cells, 24–5
 nutritional deficiencies
 childhood anemias from, 36
 iron deficiency, 36, 41
 vitamin B12 deficiency, 36
 IDA, 41
 nutritional IDA, 41
 OPSI. *See* overwhelming postsplenectomy infection
 oral riboflavin therapy, 83
 osteopenia, SCD and, 70
 osteoporosis
 Beta-thalassemia major and, 51
 SCD and, 70
 ovalocytes, 24–5
 overhydrated stomatocytosis (hydrocytosis), 105
 overwhelming postsplenectomy infection (OPSI), 103
 oxygen, hemoglobin and acquisition mechanisms, 6
 delivery mechanisms through, 6
 oxygen binding by, 5–6
 oxygen transport, 5–6
 salt bridges, 5
 oxygen binding, 5–6
 pain, with SCD, 66–7
 acute VOC, 66
 chronic, 67, 72
 management of, 72
 neuropathic, 67
 pallor, 1
 pancytopenia. *See* acquired aplastic anemia
 Pappenheimer bodies, 24–5
 parasitic, infectious diseases, 194
 parenteral iron salts, 42
 paroxysmal cold hemoglobinuria (PCH), 92–3
 acute, 93
 associated conditions with, 92
 auto-antibodies in, 92
 chronic, 93
 clinical features, 92
 Coombs test for, 92
 laboratory findings, 92
 management of, 93
 mechanisms of hemolysis, 93
 paroxysmal nocturnal hemoglobinuria (PNH), 129
 classical, 138
 treatment for, 139
 clinical presentation of, 138–9
 nitric oxide levels, 139
 renal damage, 139
 smooth muscle dystonia, 139

Index

- paroxysmal nocturnal hemoglobinuria (PNH) (cont.)
 thrombophilia, 139
 diagnostic evaluation of
 FLAER, 137–8
 GPI-AP, 137–8
 epidemiology, 137
 etiology, 137
 GPI anchors, 137
 hypoplastic, 138
 laboratory findings, 137–8
 pathophysiology, 137
 prognosis with, 139–41
 relevant cells in, 138
 thrombosis from, 137
 treatment of, 139–41
 with BMT, 141
 for classical PNH, 139
 with eculizumab, 139–41
 PCH. *See* paroxysmal cold hemoglobinuria
 Pearson syndrome, 148
 pediatric MDS, 156
 penicillamine, 124
 pentoxifylline, 123
 peripheral blood smears, review of, 24–5
 guidelines for, 29
 for IDA diagnosis, 40–1
 sideroblastic anemias and, 45
 for unstable hemoglobin disorders, 77–80
 pharmacologic therapy. *See also* erythropoiesis-stimulation agents
 iron repletion, 217–19
 IV therapy, 218–19
 oral therapies, 217
 phosphatidylserine, 9–10
 phospholipids (PS), in RBC senescence, 20
 physiologic anemia, 190
 of childhood, 35
 of infancy, 34
 PIG-A gene, 129. *See also* paroxysmal nocturnal hemoglobinuria
 pigmented gallstones, 70
 PK deficiency. *See* pyruvate kinase deficiency
 plasmapheresis, 193
 plumbism. *See* lead poisoning
 PNH. *See* paroxysmal nocturnal hemoglobinuria
 polychromasia, 24–5
 polysaccharide-iron complex, 217
 post-operative care, fever and, 225
 postoperative thrombosis, 225
 post-transfusion purpura (PTP), 214
 prasugrel, 116
 PRCA. *See* pure red cell aplasia
 precipitated hemoglobins, 5
 pregnancy, anemia during
 AIHA, 191
 clinical presentation, 191
 diagnostic evaluation, 191–2
 epidemiology of, 190
 folate deficiency, 192
 HELLP, 191
 hemolytic anemias, 191–2
 HUS, 191
 from iron deficiency, 190
 iron replacement, 192–3
 lab findings, 191–2
 MAHA, 191
 megaloblastic anemia, 190
 pathophysiology, 190
 physiologic anemia, 190
 sickle cell anemia, 192
 sickle cell hemoglobinopathies, 190–1
 thalassemia syndromes during, 192
 treatment of, 192–3
 with plasmapheresis, 193
 vitamin B12 deficiency, 192
 priapism, 70, 73
 primaquine, 168
 primary MDS, 156
 primary PRCA, 133–4
 proerythroblasts, 16
 reticulocytes and, 23
 proliferative retinopathy, 69–70
 prosthetic cardiac valves, hemolytic anemia from, 122–3
 clinical features, 122
 epidemiology of, 122
 history of, 122
 pathophysiology, 122
 treatment of, 122–3
 proton pump inhibitors, 31
 PS. *See* phospholipids
 PTP. *See* post-transfusion purpura
 pulmonary hypertension (HTN), 68–9, 73
 pulmonary system, physical examination of, 32
 pure red cell aplasia (PRCA), 132–4
 classic causes of, 132
 clinical presentation of, 132–3
 diagnostic evaluation of, 132–3
 epidemiology of, 132
 etiology of, 132
 laboratory findings, 133
 parvovirus B19 infection and, 132
 pathogenesis of, 132
 thymoma and, 132–3
 transient erythroblastopenia of childhood, 132
 treatment and prognosis, 133–4
 with corticosteroid therapy, 133–4
 for primary PRCA, 133–4
 for secondary PRCA, 133
 with thymectomy, 133
 pyruvate kinase (PK) deficiency, 37
 RA. *See* rheumatoid arthritis
 Rapoport-Leubering shunt, 10
 RBCs. *See* red blood cells
 RCC. *See* red cell concentrates
 RCE. *See* red cell exchange
 reactive oxygen species (ROS), RBC senescence, 20
 recombinant human erythropoietin (rhEPO), 172, 174–7
 iron supplementation with, 177
 red blood cell count
 EPO and, 14–16, 23
 laboratory assessments, 2
 MCV, 2
 reticulocyte count, 2
 red blood cells (RBCs)
 childhood anemias and, 35
 cytoskeleton for, 8–10
 decrease in mass, 1
 destruction of, 11–12, 21
 bilirubin levels, 12
 extravascular, 12
 geometric hypothesis, 12
 immunological hypothesis, 12
 metabolic hypothesis, 11–12
 rates of, 12
 through reticuloendothelial system clearance, 21
 Embden-Meyerhof pathway, 10
 enzymatic metabolism, 10–11
 essential components of, 3
 flippases, 9–10
 floppases, 9–10
 hemolysis stages for, 12
 hemolytic anemia in children
 from enzyme disorders, 37
 favism, 37
 G6PD deficiency, 37
 HS, 37
 from membrane disorders, 37
 PK deficiency, 37
 HMPS and, 11
 homeostasis for, 10–11
 hypoplastic disorders, 38
 DBA, 38
 TEC of childhood, 38
 lifespan of, 19–20
 MCV of, 24
 membrane for, 8–10
 components of, 9–10
 hemolytic anemia in children and, from disorders of, 37
 lipid components, 9–10
 during reticulocyte maturation, 17
 spectrins, 10
 transmembrane proteins, 9
 phosphatidylserine, 9–10
 proerythroblasts, 16
 Rapoport-Leubering shunt, 10
 reticulocyte maturation, 16–17, 19
 enucleation in, 16–17
 plasma membrane during, 17
 scramblases, 9–10
 senescence, 20–1
 CD47 protein activity, 20–1
 hemichromes and, 20
 loss of membrane surface during, 20
 PS activity, 20
 ROS and, 20
 siderosomes, 24–5
 synthesis of, 11–12
 terminal erythroid differentiation, 16
 erythroblastic islands in, 16
 heme in, 16
 iron in, 16
 transfusions, xi
 engineered stem cells in, xi
 red cell antibodies, 203
 red cell concentrates (RCC), 201
 red cell exchange (RCE), 204
 red cell membrane disorders
 classification criteria for, 100
 HS, 100–3
 hemolytic anemia in children and, 37
 red cell transfusion therapy
 after acute large volume blood loss, 202
 case study, 205
 in children, 205
 dosage of red cells, 201–2
 epidemiology, 201
 in neonates, 205
 in normovolemic anemia, 202–4
 chronic anemia and, 203–4
 irradiation, 204
 leukoreduction, 204
 phenotype matching, 203–4
 red cell exchange (RCE), 204
 red cell genotyping, 203–4
 washed red cells, 204
 red cell antibodies, 203
 storage duration, 201
 transfusion incidents rates (TIR), 201
 renal damage, with PNH, 139
 renal transplantation, for aHUS, 120
 respiratory system, with SCD, 68–9
 reticulocyte count, 2, 24–30
 MCV and, 24–30

Index

- reticulocyte index (RPI), 24–30
 reticulocyte maturation, 16–17, 19
 enucleation in, 16–17
 plasma membrane during, 17
 proerythroblasts and, 23
 reticuloendothelial system, 21
 retinopathy, with SCD, 69–70, 73
 non-proliferative, 69
 proliferative, 69–70
 Rh null disease, 106
 rhEPO. *See* recombinant human erythropoietin
 rheumatoid arthritis (RA), 150, 194
 ribavirin therapy, 168
 ribosomopathies. *See* 5q-syndrome MDS;
 Diamond-Blackfan anemia; Schwachman-Diamond syndrome
 Right Upper Quadrant Syndrome, 70
 ring sideroblastic anemias, 44
 rituximab, 89, 91, 93, 119
 ROS. *See* reactive oxygen species
 rouleaux formation, 24–5
 RPI, 24–30
- salt bridges, 5
 salvage therapy, 89–91
 SAO. *See* Southeast Asian ovalocytosis
 sarcoidosis, 194
 SBDS gene. *See* Schwachman-Bodian-Diamond syndrome gene
 SCD. *See* Sickle Cell Disease
 schistocytes, 24–5
 in TTP, 113–14
 Schwachman-Bodian-Diamond syndrome (SBDS) gene, 147–8
 Schwachman-Diamond syndrome (SDS), 143–7
 clinical presentation, 147
 diagnosis of, 147
 management of, 148
 ribosomes, 147–8
 SCN. *See* severe congenital neutropenia
 scramblases, 9–10
 SDS. *See* Schwachman-Diamond syndrome
 secondary MDS, 156
 HSCT and, 182–3
 secondary PRCA, 133
 secondary thrombotic microangiopathy, 114
 pathophysiology, 116
 treatment for, 120
 second-line therapies
 for aAA, 131–2
 for WAIHA, 89
 senescence, for RBCs, 20–1
- CD47 protein activity, 20–1
 hemichromes and, 20
 loss of membrane surface during, 20
 PS activity, 20
 ROS and, 20
 septic transfusion reactions, 212–13
 severe anemias. *See also specific anemias*
 causes of, 1
 severe congenital neutropenia (SCN), 148
 Shiga toxin-producing *Escherichia coli*-hemolytic uremic syndrome (STEC-HUS), 113
 clinical presentation of, 117
 diagnostic evaluation, 118
 laboratory findings, 118
 pathophysiology, 115–16
 treatment for, 119
 sickle cell anemia
 hemolytic anemia in children and, 37–8
 during pregnancy, 192
 prognosis with, 74
 Sickle Cell Disease (SCD)
 ACS and, 68, 73
 AVN and, 70, 73
 cardiovascular system with, 70
 central nervous system with, 69–70
 brain issues, 69
 eye issues, 69–70
 neurocognitive impairments, 69
 chronic leg ulcers and, 70, 73
 conjunctiva with, 69–70
 dactylitis and, 70, 73
 functional asplenia and, 70, 73
 gastrointestinal system with, 70, 73
 genitourinary system with, 70
 hematuria and, 70, 73
 hemolytic transfusion reactions with, 210
 hydroxyurea and, 72
 hyposthenuria and, 70
 management of, 72–3
 Moyamoya syndrome, 69
 musculoskeletal system with, 70
 osteopenia and, 70
 osteoporosis and, 70
 pain with, 66–7
 acute VOC, 66
 chronic, 67, 72
 management of, 72
 neuropathic, 67
 pigmented gallstones, 70
 prevalence of, 66
 priapism and, 70, 73
 prognosis with, 74
- pulmonary HTN and, 68–9, 73
 respiratory systems with, 68–9
 retinopathy with, 69–70, 73
 non-proliferative, 69
 proliferative, 69–70
 Right Upper Quadrant Syndrome, 70
 sickle nephropathy and, 70, 73
 silent cerebral infarcts and, 69
 skin issues and, 70
 strokes with, 69, 73
 sickle cell syndromes. *See also*
 structural hemoglobinopathies
 clinical presentation of, 66–70
 diagnostic evaluation of, 71–2
 through DNA evaluation, 71
 through laboratory testing, 71
 through newborn screening, 72
 through prenatal diagnosis, 72
 epidemiology of, 66
 etiology of, 66
 hemoglobin electrophoresis and, 71
 pathophysiology, 66
 sickle cells, 24–5
 sickle nephropathy and, 70, 73
 sideroblastic anemias
 acquired, 44
 causes of, 45
 pathophysiology, 44–5
 prognosis of, 46
 treatment of, 46
 case study for, 47
 clinical presentation of, 45
 with dyserythropoiesis, 45
 defined, 44
 diagnostic evaluation of, 45–6
 through bone marrow examination, 45–6
 from iron overload, 45
 through peripheral blood smear review, 45
 epidemiology of, 44
 etiology of, 44
 hereditary
 causes of, 44
 pathophysiology, 44
 prognosis for, 46
 treatment of, 46
 idiopathic, 46
 myelodysplastic syndromes and, 44, 46
 pathophysiology, 44–5
 acquired, 44–5
 hereditary, 44
 prognosis for, 46
 ring, 44
 treatment of, 46
 silent cerebral infarcts, 69
 sitosterolemia, 106
- skin
 physical examination of, 32
 with SCD, 70
 smooth muscle dystonia, 139
 solid malignancies, 194
 Southeast Asian ovalocytosis (SAO), 104
 spectrins, 10
 in HE pathophysiology, 104
 in HPP pathophysiology, 104
 spherocytes, 24–5
 spleen, 21
 splenectomy, 223–6
 for AIHA, 223
 complications of, 224–5
 postoperative thrombosis, 225
 splenic vein thrombosis, 225
 thromboembolism, 225
 for Felty Syndrome, 224
 for HS, 103, 223
 laparoscopic, 224
 OPSI after, 103
 post-operative care, 225–6
 antibiotics in, 225
 fever and, 225
 vaccinations in, 226
 for thalassemias, 223–4
 for WAIHA, 89
 splenic cords, 21
 splenic vein thrombosis, 225
 splenomegaly, HS and, 103
 spur cells, 24–5
 STEC-HUS. *See* Shiga toxin-producing *Escherichia coli*-hemolytic uremic syndrome
 stem cells. *See also* engineered stem cells
 in DC therapy, 146
 farming, 233
 steroid therapy, for CAD, 91–2
 stomatocytes, 24–5
 strokes, SCD and, 69, 73
 structural hemoglobinopathies
 defined, 76
 diagnosis of, 77
 high affinity hemoglobin disorders, 76, 80–1
 diagnosis of, 80–1
 pathophysiology, 80
 treatment of, 81
 low affinity hemoglobin disorders, 76, 81
 cyanosis and, 81
 diagnosis of, 81
 pathophysiology, 81
 treatment for, 81
 methemoglobinemia, 81–3
 causes of, 82
 clinical presentation of, 81–2
 diagnosis of, 82
 pathophysiology, 82
 treatment of, 82–3

Index

- systemic diseases, 194
 clinical presentation, 194
 pathophysiology, 195–8
 systemic lupus erythematosus, 194
- TACO. *See* transfusion
 associated circulatory
 overload
- TA-GVHD. *See* transfusion
 associated graft-versus-
 host-disease
- Tangier disease, 106
- TAR syndrome. *See*
 thrombocytopenia-
 absent radius syndrome
- target cells, 24–5
- tear drop cells, 24–5
- TEC of childhood. *See* transient
 erythroblastopenia of
 childhood
- TEE. *See* intraoperative
 transesophageal
 echocardiography
- telomere length, 129–30. *See also*
 dyskeratosis congenita
- terminal erythroid
 differentiation, 16
 erythroblastic islands in, 16
 heme in, 16
 iron in, 16
- thalassemia syndromes, 48. *See*
 also Alpha-thalassemia;
 Beta-thalassemia
 causes of, 48
 origins of, 48
 during pregnancy, 192
 prevalence of, 48
 splenectomy for, 223–4
- thermal injury-induced
 hemolysis, 123
- thrombocytopenia-absent radius
 (TAR) syndrome, 148
- thromboembolism, 225
- thrombophilia, 139
- thrombosis, from PNH, 137
- thrombotic microangiopathic
 hemolytic anemia
 (TMA), 181–2
- thrombotic thrombocytopenic
 purpura (TTP), 113–14
 autoimmune, 113
 clinical presentation of,
 116–17
 congenital, 113, 119
 diagnostic evaluation of, 118
 HSCT and, 181
 laboratory findings, 118
 pathophysiology, 114–15
 treatment for, 118–19
 with rituximab, 119
- thymectomy, 133
- thyroid disease, 198
- thyromegaly, 32
- TIBC. *See* total iron-binding
 capacity
- ticlopidine, 116
- TIR. *See* transfusion incidents
 rates
- TMA. *See* thrombotic
 microangiopathic
 hemolytic anemia
- TNF- α . *See* tumor necrosis factor
 alpha
- total iron-binding capacity
 (TIBC), 40–1
- transferrin saturation (TSAT)
 testing, 40–1
- transfusion associated circulatory
 overload (TACO), 211
- transfusion associated graft-
 versus-host-disease
 (TA-GVHD), 213
- transfusion incidents rates (TIR),
 201
- transfusion reactions
 acute clinical symptoms, 208
 with ALI, 211
 allergic reactions, clinical
 presentation of, 211–12
 classification of, 207–8
- febrile non-hemolytic, 210–11
- hemolytic, 208–9
 delayed, 209–10
 extravascular, 209
 intravascular, 209
- hyperkalemia, 214
- hypokalemia, 214
- hypothermia, 214
- metabolic derangements,
 213–14
- pathogen reduction, 213
- post-transfusion purpura
 (PTP), 214
- practice requirements, 207
- prevention strategies for, 208
- septic, 212–13
- in sickle cell disease, 210
- TACO, 211
- TA-GVHD, 213
- TRALI, 210
- transfusions. *See* blood
 transfusions
- transient erythroblastopenia
 (TEC) of childhood, 38,
 132
- transmembrane proteins, in
 RBCs, 9
- TSAT testing. *See* transferrin
 saturation testing
- TTP. *See* thrombotic
 thrombocytopenic
 purpura
- tumor necrosis factor alpha
 (TNF- α), 186
- twin-twin transfusions, 35
- unstable hemoglobins, 76
- vaccinations, after splenectomy,
 226
- vasculitis, 194
- viral, infectious disease, 194
- vitamin B12
 childhood anemias from
 deficiencies of, 36
- as hematinic, xi
- HIV associated with anemia,
 167
- megaloblastic macrocytic
 anemias and, 59–63
- during pregnancy, 192
- severe anemias from, 1
- VOC. *See* Acute Vaso-Occlusive
 Crisis
- volume homeostasis disorders,
 105
- Von Willebrand's disease, 41
- warm AIHA (WAIHA), 84–91
 associated conditions for, 87–8
 drug-induced, 88
 clinical features of, 84
 Coombs test for, 84–6
 clinical serological
 associations, 86
 hemolysis mechanisms,
 87
 haptenic reactions, 87
 NIPA, 87
 laboratory findings for, 84
 management of, 91
 with corticosteroids, 89
 with RBC transfusions, 87
 with rituximab, 89
 with salvage therapy, 89–90
 with second-line therapy, 89
 with splenectomy, 89
 microspherocytosis and, 84
 warm-reacting antibodies, 86
- washed red cells, 204
- women
 IDA and, 41
 Von Willebrand's disease in,
 41
- World Health Organization
 (WHO), classification of
 MDS and MDS/MPN,
 160
- zidovudine (AZT), 167–8